Future Outlook for PD-1 Inhibitor Use in ESCC and Gastric Cancer

This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the management of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (GEJ) cancers. The panel notes that PD-1 inhibitors are now well established in the first-line setting for appropriate patients, and ongoing studies are evaluating their potential incorporation into perioperative and adjuvant treatment strategies. The discussion also highlights interest in combining PD-1 inhibitors with emerging targeted agents or novel immunotherapy approaches as clinical evidence develops. For gastric and GEJ cancers, increasing use of molecular profiling, such as assessment of PD-L1 expression and MSI status, may help refine treatment selection and identify patients most likely to benefit from specific therapeutic approaches. Throughout the segment, the panel underscores the importance of multidisciplinary coordination as the treatment landscape becomes more complex. Overall, the conversation outlines key research directions that may help shape how PD-1 inhibitors are integrated into future care pathways.